German medical cannabis market faces uncertainty over new reimbursement rules
Germany's medical cannabis market, estimated at DKK 8.5 billion, remains uncertain following the implementation of new reimbursement rules on July 30.
STENOCARE A/S has provided an update on the German medical cannabis market, highlighting ongoing complexity and uncertainty. New reimbursement rules, effective from July 30, have resulted in differing interpretations among market participants and authorities.
Market analysts, such as Prohibition Partners, project the German medical cannabis market to reach approximately DKK 8.5 billion by 2026. The recent introduction of new rules aims to regulate and clarify reimbursement procedures for medical cannabis products.
The ambiguity surrounding the application of these rules impacts companies operating in the sector, including STENOCARE A/S. The extent to which medical cannabis can be reimbursed and which products will be eligible remains unclear pending further clarification.
This situation could affect the availability of medical cannabis for patients in Germany. STENOCARE A/S is closely monitoring developments and awaits further guidance from regulatory bodies to understand the precise implications for its operations and the broader market.